Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label, Phase 3 Long-term Safety Study of Topically Applied Sofpironium Bromide (BBI-4000) Gel, 5% and 15% in Subjects With Axillary Hyperhidrosis

NCT03627468 is registered in ClinicalTrials.gov with Botanix Pharmaceuticals as lead sponsor.

NCT NCT03627468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03627468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label, Phase 3 Long-term Safety Study of Topically Applied Sofpironium Bromide (BBI-4000) Gel, 5% and 15% in Subjects With Axillary Hyperhidrosis
Lead sponsor
Botanix Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
September 5, 2018
Completion date
January 27, 2020
Enrollment
300 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

primary axillary hyperhidrosis